Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that it joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective after the U.S. market close on June 26, 2026.
Membership, based on FTSE Russell’s market-cap rankings and style attributes, lasts until the next semi-annual reconstitution and brings automatic inclusion in related growth and value indexes.
Russell indexes are widely used benchmarks, with approximately $12.2 trillion in assets tied to their U.S. indexes.
Positive
- OBIO added to Russell 3000 Index after June 26, 2026 close
- OBIO added to Russell 2000 Index via Russell 3000 membership
- Index membership based on FTSE Russell market-cap rankings and style attributes
- Exposure to U.S. benchmarks with about $12.2 trillion in benchmarked assets
Negative
- None.
News Market Reaction – OBIO
In the Jun 29 session, OBIO gained 12.03%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.2% during that session. Argus tracked a trough of -6.5% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Equity inducement grants | Neutral | -1.3% | New-hire stock option inducement grants under Nasdaq Listing Rule 5635(c)(4). |
| May 19 | Conference participation | Neutral | +2.3% | Jefferies Global Healthcare Conference fireside chat and investor meetings. |
| May 12 | Quarterly earnings update | Neutral | +0.0% | Q1 2026 financials, cash runway into Q4 2027, and trial progress. |
| May 12 | Clinical trial timeline | Positive | +3.8% | BACKBEAT Trial enrollment and data timing under FDA Breakthrough program. |
| May 06 | Strategic financing | Positive | +2.5% | Completion of $15M Ligand tranche, totaling $40M strategic capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OBIO news has generally aligned with modestly positive or neutral price reactions, with only one minor divergence on a routine compensation update.
Key Terms
russell 3000® index financial
russell 2000® index financial
market capitalization financial
index funds financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026.
The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are part of FTSE Russell, a leading global index provider. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website here.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and a global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth, and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com
